Leading the omega-3 pharma market
Reference standard for prescription omega-3-acid ethyl esters
Over two decades ago BASF introduced to the market Omacor®/Lovaza™, the first FDA and EU approved omega-3 based prescription drug. Our product is now represented in over 80 countries. We became world leaders in high-concentrate Omega-3 fatty acids for pharmaceuticals.
Prescription omega-3s are shown to improve:
- Post-myocardial infarction
We offer generic omega-3-acid ethyl esters (K85EE) as an Active Pharmaceutical Ingredient (API).
BASF delivers premium products
- Pioneering in pharmaceutical use of omega-3
- Long history of production and delivery of Omacor®/LovazaTM, the first FDA and EU approved omega-3 based prescription drug
- World leading expertise, experience & support for: analysis, regulatory control, production and supply
- Long-term strategic commitment to the business
Discover our Product Range
|K85EE||Information & Certificates|
|K85EE Omega-3-acid ethyl esters||Information & Certificates|
|Omega 3 fatty acid ethyl ester||Information & Certificates|